212 related articles for article (PubMed ID: 18321314)
1. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
Bartsch G; Horninger W; Klocker H; Pelzer A; Bektic J; Oberaigner W; Schennach H; Schäfer G; Frauscher F; Boniol M; Severi G; Robertson C; Boyle P;
BJU Int; 2008 Apr; 101(7):809-16. PubMed ID: 18321314
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
3. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
5. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.
Bartsch G; Horninger W; Klocker H; Reissigl A; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P;
Urology; 2001 Sep; 58(3):417-24. PubMed ID: 11549491
[TBL] [Abstract][Full Text] [Related]
7. Are survival rates for Tyrol published in the Eurocare studies biased?
Oberaigner W; Siebert U
Acta Oncol; 2009; 48(7):984-91. PubMed ID: 19714522
[TBL] [Abstract][Full Text] [Related]
8. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
9. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
10. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Aigner F; Mitterberger M; Steiner E; Bartsch G; Horninger W
BJU Int; 2008 May; 101(10):1223-6. PubMed ID: 18190631
[TBL] [Abstract][Full Text] [Related]
11. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
14. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
Di Matteo L; Di Matteo R
Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
[TBL] [Abstract][Full Text] [Related]
15. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
16. The influence of statin medications on prostate-specific antigen levels.
Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
[TBL] [Abstract][Full Text] [Related]
17. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
18. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
19. Early detection of prostate cancer. Decreasing the mortality rate.
Oesterling JE
Minn Med; 1996 Apr; 79(4):46-9. PubMed ID: 8637492
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
